Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2018 2
2019 2
2020 2
2021 3
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
APASL consensus statements and recommendation on treatment of hepatitis C.
Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK. Omata M, et al. Hepatol Int. 2016 Sep;10(5):702-26. doi: 10.1007/s12072-016-9717-6. Epub 2016 Apr 29. Hepatol Int. 2016. PMID: 27130427 Free PMC article. Review.
Discordance of HER2 Expression and/or Amplification on Repeat Testing.
DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. DiPeri TP, et al. Mol Cancer Ther. 2023 Aug 1;22(8):976-984. doi: 10.1158/1535-7163.MCT-22-0630. Mol Cancer Ther. 2023. PMID: 37339271 Free PMC article.
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.
Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Al-Mahtab M, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK. Omata M, et al. Hepatol Int. 2016 Sep;10(5):681-701. doi: 10.1007/s12072-016-9736-3. Epub 2016 May 26. Hepatol Int. 2016. PMID: 27229718 Free PMC article. Review.
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattan S, Blanc JF, Lee KH, Maur M, Pant S, Kudo M, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillén-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Delord JP. Chan SL, et al. J Exp Clin Cancer Res. 2022 Jun 2;41(1):189. doi: 10.1186/s13046-022-02383-5. J Exp Clin Cancer Res. 2022. PMID: 35655320 Free PMC article. Clinical Trial.
Observation of the B_{s}^{0}→X(3872)ϕ Decay.
Sirunyan AM, Tumasyan A, Adam W, Ambrogi F, Bergauer T, Dragicevic M, Erö J, Escalante Del Valle A, Frühwirth R, Jeitler M, Krammer N, Lechner L, Liko D, Madlener T, Mikulec I, Pitters FM, Rad N, Schieck J, Schöfbeck R, Spanring M, Templ S, Waltenberger W, Wulz CE, Zarucki M, Chekhovsky V, Litomin A, Makarenko V, Suarez Gonzalez J, Darwish MR, De Wolf EA, Di Croce D, Janssen X, Kello T, Lelek A, Pieters M, Rejeb Sfar H, Van Haevermaet H, Van Mechelen P, Van Putte S, Van Remortel N, Blekman F, Bols ES, Chhibra SS, D'Hondt J, De Clercq J, Lontkovskyi D, Lowette S, Marchesini I, Moortgat S, Morton A, Python Q, Tavernier S, Van Doninck W, Van Mulders P, Beghin D, Bilin B, Clerbaux B, De Lentdecker G, Delannoy H, Dorney B, Favart L, Grebenyuk A, Kalsi AK, Makarenko I, Moureaux L, Pétré L, Popov A, Postiau N, Starling E, Thomas L, Vander Velde C, Vanlaer P, Vannerom D, Wezenbeek L, Cornelis T, Dobur D, Gruchala M, Khvastunov I, Niedziela M, Roskas C, Skovpen K, Tytgat M, Verbeke W, Vermassen B, Vit M, Bruno G, Bury F, Caputo C, David P, Delaere C, Delcourt M, Donertas IS, Giammanco A, Lemaitre V, Mondal K, Prisciandaro J, Taliercio A, Teklishyn M, Vischia P, Wuyckens S, Zobec J, Alves G… See abstract for full author list ➔ Sirunyan AM, et al. Phys Rev Lett. 2020 Oct 9;125(15):152001. doi: 10.1103/PhysRevLett.125.152001. Phys Rev Lett. 2020. PMID: 33095627
Using a data sample of proton-proton collisions at sqrt[s]=13 TeV, corresponding to an integrated luminosity of 140 fb^{-1} collected by the CMS experiment in 2016-2018, the B_{s}^{0}X(3872) decay is observed. Decays into J/psipi^{+}pi^{-} and K^{+}K^{-} are used to …
Using a data sample of proton-proton collisions at sqrt[s]=13 TeV, corresponding to an integrated luminosity of 140 fb^{-1} collected by the …
14 results